Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 16INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Classical hematology 3Other hematologic neoplasm 2Myeloid 1

Conditions

Thrombocytopenia 3Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia 1Jacobs syndrome 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × eltrombopag × Clear all
NCT01890746 2019-09-11

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Novartis

Phase 2 Completed
148 enrolled 42 charts
Classical hematologyOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT01440374 2017-06-05

ASPIRE

Novartis

Phase 2 Completed
162 enrolled 24 charts
Classical hematologyMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT00102726 2017-03-23

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

GlaxoSmithKline

Phase 2 Completed
183 enrolled
Classical hematology

Jacobs syndrome, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡